Abstract
We welcome the publication of the British HIV Association(BHIVA) and British Infection Association (BIA) opportun-istic infection guidelines in the September issue [1], butwish to comment on three recommendations for manage-ment of cryptococcal meningitis in HIV infection (CM).In contrast to the Infectious Diseases Society of America(IDSA) and recent World Health Organization (WHO) guide-lines on induction treatment of CM [2,3] which recommendconventional amphotericin B deoxycholate (AmBd) at 0.7–1 mg/kg/day with flucytosine (5FC) based on robust phaseII and phase III randomized controlled trial (RCT) data, theUK panel recommends liposomal amphotericin B (4 mg/kg/day) in place of AmBd based on a shorter time to cere-brospinal fluid (CSF) sterilization in a very small RCT(
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
